1. Home
  2. TDF vs TTRX Comparison

TDF vs TTRX Comparison

Compare TDF & TTRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Templeton Dragon Fund Inc.

TDF

Templeton Dragon Fund Inc.

BUY

Current Price

$9.40

Market Cap

250.8M

Sector

Finance

ML Signal

BUY

Logo Turn Therapeutics Inc.

TTRX

Turn Therapeutics Inc.

N/A

Current Price

$11.34

Market Cap

298.8M

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
TDF
TTRX
Founded
1994
2015
Country
Singapore
United States
Employees
N/A
N/A
Industry
Finance/Investors Services
Biotechnology: Pharmaceutical Preparations
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
250.8M
298.8M
IPO Year
N/A
2025

Fundamental Metrics

Financial Performance
Metric
TDF
TTRX
Price
$9.40
$11.34
Analyst Decision
Strong Buy
Analyst Count
0
2
Target Price
N/A
★ $25.00
AVG Volume (30 Days)
46.2K
★ 131.9K
Earning Date
01-01-0001
11-25-2026
Dividend Yield
N/A
N/A
EPS Growth
★ N/A
N/A
EPS
★ N/A
N/A
Revenue
N/A
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
$900.00
P/E Ratio
N/A
★ N/A
Revenue Growth
N/A
N/A
52 Week Low
$9.40
$2.57
52 Week High
$12.20
$16.45

Technical Indicators

Market Signals
Indicator
TDF
TTRX
Relative Strength Index (RSI) 22.65 44.67
Support Level N/A $9.02
Resistance Level $11.17 $14.39
Average True Range (ATR) 0.20 1.44
MACD -0.03 -0.40
Stochastic Oscillator 5.22 5.97

Price Performance

Historical Comparison
TDF
TTRX

About TDF Templeton Dragon Fund Inc.

Templeton Dragon Fund Inc is a closed-end management investment company. The fund seeks long-term capital appreciation by investing majority of its total assets in equity securities of China companies. It invest in various sectors such as gas & consumable fuels, auto components, banks, beverages, communications equipment, healthcare equipment & supplies, restaurants & leisure, household durables and many others.

About TTRX Turn Therapeutics Inc.

Turn Therapeutics Inc is a clinical-stage biotechnology and medical device development company built around its proprietary platform technology called PermaFusion designed to enhance drug performance. The company is developing non-systemic, non-biologic topical immunomodulators for inflammatory skin disease. Its program, GX-03, is being studied for moderate-to-severe eczema based on preclinical evidence of cytokine inhibition and reduced eczema severity, as well as a favorable real-world tolerability record from prior cleared medical device indications for the same formula. GX-03 is currently being evaluated in an ongoing, randomized, double-blind, vehicle-controlled clinical study designed to assess its potential as a topical treatment for moderate-to-severe eczema.

Share on Social Networks: